Welcome!

News Feed Item

Spinal Cord Injury Global Clinical Trials Review, H2, 2014

NEW YORK, Aug. 11, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Spinal Cord Injury Global Clinical Trials Review, H2, 2014

http://www.reportlinker.com/p02280945/Spinal-Cord-Injury-Global-Clinical-Trials-Review-H2-2014.html

Spinal Cord Injury Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Spinal Cord Injury Global Clinical Trials Review, H2, 2014" provides data on the Spinal Cord Injury clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Spinal Cord Injury. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Spinal Cord Injury. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Spinal Cord Injury 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Spinal Cord Injury to Central Nervous System Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Spinal Cord Injury to Central Nervous System Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Spinal Cord Injury 25
Subjects Recruited Over a Period of Time 28
Clinical Trials by Sponsor Type 29
Prominent Sponsors 30
Top Companies Participating in Spinal Cord Injury Therapeutics Clinical Trials 31
Prominent Drugs 33
Latest Clinical Trials News on Spinal Cord Injury 34
May 19, 2014: StemCells Provides Update on Its Phase I/II Study in Spinal Cord Injury 34
Clinical Trial Profiles 35
Clinical Trial Overview of Top Companies 35
Pfizer Inc. 35
Clinical Trial Overview of Pfizer Inc. 35
Acorda Therapeutics, Inc. 36
Clinical Trial Overview of Acorda Therapeutics, Inc. 36
Allergan, Inc. 37
Clinical Trial Overview of Allergan, Inc. 37
Stem Cell Sciences UK Ltd 38
Clinical Trial Overview of Stem Cell Sciences UK Ltd 38
Neuralstem, Inc. 39
Clinical Trial Overview of Neuralstem, Inc. 39
BioAxone BioSciences Inc. 40
Clinical Trial Overview of BioAxone BioSciences Inc. 40
AOSpine International 41
Clinical Trial Overview of AOSpine International 41
K-Stemcell Co., Ltd. 42
Clinical Trial Overview of K-Stemcell Co., Ltd. 42
Daiichi Sankyo Company, Limited 43
Clinical Trial Overview of Daiichi Sankyo Company, Limited 43
Bayer AG 44
Clinical Trial Overview of Bayer AG 44
Clinical Trial Overview of Top Institutes / Government 45
U.S. Department of Veterans Affairs 45
Clinical Trial Overview of U.S. Department of Veterans Affairs 45
University of Miami 48
Clinical Trial Overview of University of Miami 48
University of Washington 49
Clinical Trial Overview of University of Washington 49
National Institute of Neurological Disorders and Stroke 50
Clinical Trial Overview of National Institute of Neurological Disorders and Stroke 50
University of British Columbia 51
Clinical Trial Overview of University of British Columbia 51
Eunice Kennedy Shriver National Institute of Child Health and Human Development 52
Clinical Trial Overview of Eunice Kennedy Shriver National Institute of Child Health and Human Development 52
China Spinal Cord Injury Network 53
Clinical Trial Overview of China Spinal Cord Injury Network 53
National Taiwan University Hospital 54
Clinical Trial Overview of National Taiwan University Hospital 54
James J. Peters Veterans Affairs Medical Center 55
Clinical Trial Overview of James J. Peters Veterans Affairs Medical Center 55
University of California, Irvine 56
Clinical Trial Overview of University of California, Irvine 56
Five Key Clinical Profiles 57
Appendix 104
Abbreviations 104
Definitions 104
Research Methodology 105
Secondary Research 105
About GlobalData 106
Contact Us 106
Disclaimer 106
Source 106

List of Tables

Spinal Cord Injury Therapeutics, Global, Clinical Trials by Region, 2014* 7
Spinal Cord Injury Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Spinal Cord Injury Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Spinal Cord Injury Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Spinal Cord Injury Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Spinal Cord Injury Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Spinal Cord Injury Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Spinal Cord Injury Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 14
Proportion of Spinal Cord Injury to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 15
Spinal Cord Injury Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Spinal Cord Injury Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Spinal Cord Injury to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 18
Spinal Cord Injury Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Spinal Cord Injury Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Spinal Cord Injury Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Spinal Cord Injury Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Spinal Cord Injury Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Spinal Cord Injury Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Spinal Cord Injury Therapeutics, Global, Suspended Clinical Trials, 2014* 25
Spinal Cord Injury Therapeutics, Global, Withdrawn Clinical Trials, 2014* 26
Spinal Cord Injury Therapeutics, Global, Terminated Clinical Trials, 2014* 27
Spinal Cord Injury Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 28
Spinal Cord Injury Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 29
Spinal Cord Injury Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 30
Spinal Cord Injury Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 32
Spinal Cord Injury Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 33
Spinal Cord Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 35
Spinal Cord Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by Acorda Therapeutics, Inc., 2014* 36
Spinal Cord Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by Allergan, Inc., 2014* 37
Spinal Cord Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by Stem Cell Sciences UK Ltd, 2014* 38
Spinal Cord Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by Neuralstem, Inc., 2014* 39
Spinal Cord Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by BioAxone BioSciences Inc., 2014* 40
Spinal Cord Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by AOSpine International, 2014* 41
Spinal Cord Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by K-Stemcell Co., Ltd., 2014* 42
Spinal Cord Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by Daiichi Sankyo Company, Limited, 2014* 43
Spinal Cord Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by Bayer AG, 2014* 44
Spinal Cord Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by U.S. Department of Veterans Affairs, 2014* 45
Spinal Cord Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Miami, 2014* 48
Spinal Cord Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Washington, 2014* 49
Spinal Cord Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by National Institute of Neurological Disorders and Stroke, 2014* 50
Spinal Cord Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by University of British Columbia, 2014* 51
Spinal Cord Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by Eunice Kennedy Shriver National Institute of Child Health and Human Development, 2014* 52
Spinal Cord Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by China Spinal Cord Injury Network, 2014* 53
Spinal Cord Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by National Taiwan University Hospital, 2014* 54
Spinal Cord Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by James J. Peters Veterans Affairs Medical Center, 2014* 55
Spinal Cord Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, Irvine, 2014* 56

List of Figures

Spinal Cord Injury Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Spinal Cord Injury Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Spinal Cord Injury Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Spinal Cord Injury Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Spinal Cord Injury Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Spinal Cord Injury Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Spinal Cord Injury Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014* 13
Spinal Cord Injury Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2014* 14
Proportion of Spinal Cord Injury to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 15
Spinal Cord Injury Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Spinal Cord Injury Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Spinal Cord Injury to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 18
Spinal Cord Injury Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Spinal Cord Injury Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Spinal Cord Injury Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Spinal Cord Injury Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Spinal Cord Injury Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Spinal Cord Injury Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Spinal Cord Injury Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 28
Spinal Cord Injury Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 29
Spinal Cord Injury Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 30
Spinal Cord Injury Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 31
Spinal Cord Injury Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 33
GlobalData Methodology 105

To order this report: Spinal Cord Injury Global Clinical Trials Review, H2, 2014
http://www.reportlinker.com/p02280945/Spinal-Cord-Injury-Global-Clinical-Trials-Review-H2-2014.html

__________________________
Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
You think you know what’s in your data. But do you? Most organizations are now aware of the business intelligence represented by their data. Data science stands to take this to a level you never thought of – literally. The techniques of data science, when used with the capabilities of Big Data technologies, can make connections you had not yet imagined, helping you discover new insights and ask new questions of your data. In his session at @ThingsExpo, Sarbjit Sarkaria, data science team lead ...
Much of the value of DevOps comes from a (renewed) focus on measurement, sharing, and continuous feedback loops. In increasingly complex DevOps workflows and environments, and especially in larger, regulated, or more crystallized organizations, these core concepts become even more critical. In his session at @DevOpsSummit at 18th Cloud Expo, Andi Mann, Chief Technology Advocate at Splunk, will show how, by focusing on 'metrics that matter,' you can provide objective, transparent, and meaningfu...
Struggling to keep up with increasing application demand? Learn how Platform as a Service (PaaS) can streamline application development processes and make resource management easy.
If there is anything we have learned by now, is that every business paves their own unique path for releasing software- every pipeline, implementation and practices are a bit different, and DevOps comes in all shapes and sizes. Software delivery practices are often comprised of set of several complementing (or even competing) methodologies – such as leveraging Agile, DevOps and even a mix of ITIL, to create the combination that’s most suitable for your organization and that maximize your busines...
In his session at @ThingsExpo, Chris Klein, CEO and Co-founder of Rachio, will discuss next generation communities that are using IoT to create more sustainable, intelligent communities. One example is Sterling Ranch, a 10,000 home development that – with the help of Siemens – will integrate IoT technology into the community to provide residents with energy and water savings as well as intelligent security. Everything from stop lights to sprinkler systems to building infrastructures will run ef...
SYS-CON Events announced today that Peak 10, Inc., a national IT infrastructure and cloud services provider, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Peak 10 provides reliable, tailored data center and network services, cloud and managed services. Its solutions are designed to scale and adapt to customers’ changing business needs, enabling them to lower costs, improve performance and focus inter...
In the world of DevOps there are ‘known good practices’ – aka ‘patterns’ – and ‘known bad practices’ – aka ‘anti-patterns.' Many of these patterns and anti-patterns have been developed from real world experience, especially by the early adopters of DevOps theory; but many are more feasible in theory than in practice, especially for more recent entrants to the DevOps scene. In this power panel at @DevOpsSummit at 18th Cloud Expo, moderated by DevOps Conference Chair Andi Mann, panelists will dis...
Up until last year, enterprises that were looking into cloud services usually undertook a long-term pilot with one of the large cloud providers, running test and dev workloads in the cloud. With cloud’s transition to mainstream adoption in 2015, and with enterprises migrating more and more workloads into the cloud and in between public and private environments, the single-provider approach must be revisited. In his session at 18th Cloud Expo, Yoav Mor, multi-cloud solution evangelist at Cloudy...
Artificial Intelligence has the potential to massively disrupt IoT. In his session at 18th Cloud Expo, AJ Abdallat, CEO of Beyond AI, will discuss what the five main drivers are in Artificial Intelligence that could shape the future of the Internet of Things. AJ Abdallat is CEO of Beyond AI. He has over 20 years of management experience in the fields of artificial intelligence, sensors, instruments, devices and software for telecommunications, life sciences, environmental monitoring, process...
Increasing IoT connectivity is forcing enterprises to find elegant solutions to organize and visualize all incoming data from these connected devices with re-configurable dashboard widgets to effectively allow rapid decision-making for everything from immediate actions in tactical situations to strategic analysis and reporting. In his session at 18th Cloud Expo, Shikhir Singh, Senior Developer Relations Manager at Sencha, will discuss how to create HTML5 dashboards that interact with IoT devic...
See storage differently! Storage performance problems have only gotten worse and harder to solve as applications have become largely virtualized and moved to a cloud-based infrastructure. Storage performance in a virtualized environment is not just about IOPS, it is about how well that potential performance is guaranteed to individual VMs for these apps as the number of VMs keep going up real time. In his session at 18th Cloud Expo, Dhiraj Sehgal, in product and marketing at Tintri, will discu...
So, you bought into the current machine learning craze and went on to collect millions/billions of records from this promising new data source. Now, what do you do with them? Too often, the abundance of data quickly turns into an abundance of problems. How do you extract that "magic essence" from your data without falling into the common pitfalls? In her session at @ThingsExpo, Natalia Ponomareva, Software Engineer at Google, will provide tips on how to be successful in large scale machine lear...
SYS-CON Events announced today that SoftLayer, an IBM Company, has been named “Gold Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. SoftLayer, an IBM Company, provides cloud infrastructure as a service from a growing number of data centers and network points of presence around the world. SoftLayer’s customers range from Web startups to global enterprises.
The IoTs will challenge the status quo of how IT and development organizations operate. Or will it? Certainly the fog layer of IoT requires special insights about data ontology, security and transactional integrity. But the developmental challenges are the same: People, Process and Platform. In his session at @ThingsExpo, Craig Sproule, CEO of Metavine, will demonstrate how to move beyond today's coding paradigm and share the must-have mindsets for removing complexity from the development proc...
SYS-CON Events announced today that Ericsson has been named “Gold Sponsor” of SYS-CON's @ThingsExpo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. Ericsson is a world leader in the rapidly changing environment of communications technology – providing equipment, software and services to enable transformation through mobility. Some 40 percent of global mobile traffic runs through networks we have supplied. More than 1 billion subscribers around the world re...